UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy

Rheumatology (Oxford, England), 2021-05, Vol.60 (5), p.2461-2466

2021

Volltextzugriff (PDF)

Defining the Optimal Strategies for Achieving Drug-Free Remission in Rheumatoid Arthritis: A Narrative Review

Healthcare (Basel), 2021-12, Vol.9 (12), p.1726

2021

Volltextzugriff (PDF)

Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses

Rheumatic & musculoskeletal diseases open, 2022-03, Vol.8 (1), p.e002050

2022

Volltextzugriff (PDF)

Clinical trajectories of hand function impairment in systemic sclerosis: an unmet clinical need across disease subsets

Rheumatic & musculoskeletal diseases open, 2024-01, Vol.10 (1), p.e003216

2024

Volltextzugriff (PDF)

After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?: Table 1

Annals of the rheumatic diseases, 2012-06, Vol.71 (6), p.799-803

2012

Volltextzugriff (PDF)

Discontinuation of biologics in patients with rheumatoid arthritis

Clinical and experimental rheumatology, 2013-07, Vol.31 (4 Suppl 78), p.S22

2013

Volltextzugriff (PDF)

Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study

Annals of the rheumatic diseases, 2012-08, Vol.71 (8), p.1316-1321

2012

Volltextzugriff (PDF)

P139 Rituximab in a large UK centre during the COVID-19 pandemic: the effects of employing a reduced dosing regimen on clinical response in Rheumatoid Arthritis patients

Rheumatology (Oxford, England), 2023-04, Vol.62 (Supplement_2)

2023

Volltextzugriff (PDF)

P12 Clinical responses, B cell depletion and treatment outcomes following rituximab biosimilar switch in RA: is there value in switching back?

Rheumatology (Oxford, England), 2020-04, Vol.59 (Supplement_2)

2020

Volltextzugriff (PDF)

Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments

Annals of the rheumatic diseases, 2011-05, Vol.70 (5), p.792-798

2011

Volltextzugriff (PDF)

Poly‐Refractory Rheumatoid Arthritis: An Uncommon Subset of Difficult to Treat Disease With Distinct Inflammatory and Noninflammatory Phenotypes

Arthritis & rheumatology (Hoboken, N.J.), 2024-04, Vol.76 (4), p.510-521

2024

Volltextzugriff (PDF)

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study

The Lancet. Rheumatology, 2023-02, Vol.5 (2), p.e88-e98

2023

Volltextzugriff (PDF)

Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis

Rheumatology (Oxford, England), 2021-08, Vol.60 (8), p.3679-3688

2021

Volltextzugriff (PDF)

Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?

Annals of the rheumatic diseases, 2010-09, Vol.69 (9), p.1636-1642

2010

Volltextzugriff (PDF)

COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1

The Lancet. Rheumatology, 2022-03, Vol.4 (3), p.e171-e172

2022

Volltextzugriff (PDF)

After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?

Annals of the Rheumatic Diseases, 2012-06, Vol.71 (6), p.799-803

2012

Volltextzugriff (PDF)

191 Effectiveness and safety of switch to rituximab biosimilar with rheumatoid arthritis. a single centre experience

Rheumatology (Oxford, England), 2019-04, Vol.58 (Supplement_3)

2019

Volltextzugriff (PDF)

Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis

Rheumatology (Oxford, England), 2010-10, Vol.49 (10), p.1971-1974

2010

Volltextzugriff (PDF)

Effect of Fatigue, Older Age, Higher Body Mass Index, and Female Sex on Disability in Early Rheumatoid Arthritis in the Treatment‐to‐Target Era

Arthritis care & research (2010), 2018-03, Vol.70 (3), p.361-368

2018

Volltextzugriff (PDF)

After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?

Postgraduate Medical Journal, 2012-08, Vol.88 (1042), p.482-486

2012

Volltextzugriff (PDF)

The clinical, imaging and immunological phenotype of remission in inflammatory arthritis

Saleem, Benazir

2011

Volltextzugriff (PDF)

Remission in inflammatory arthritis: a new immunological target

Immunotherapy, 2011-04, Vol.3 (4), p.459-463

2011

Volltextzugriff (PDF)

Infliximab for rheumatoid arthritis

Expert review of clinical immunology, 2006-03, Vol.2 (2), p.193-207

2006

Volltextzugriff (PDF)

Biomarkers: Strategies to predict outcome of rheumatoid arthritis

Drug discovery today. Therapeutic strategies, 2006, Vol.3 (1), p.11-16

2006

Volltextzugriff (PDF)

Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease‐modifying antirheumatic drugs: A clinical and imaging comparative study

Arthritis and rheumatism, 2009-07, Vol.60 (7), p.1915-1922

2009

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(23)

Publikationsform

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(18)
Rheumatology
(16)
Humans
(13)
Rheumatoid Arthritis
(12)
Antirheumatic Agents - Therapeutic Use
(11)
Arthritis, Rheumatoid - Drug Therapy
(11)
Biological And Medical Sciences
(7)
Male
(7)
Medical Sciences
(7)
Remission Induction
(7)
Treatment Outcome
(7)
Diseases Of The Osteoarticular System
(6)
Female
(6)
Inflammation
(6)
Middle Aged
(6)
Remission
(6)
Severity Of Illness Index
(6)
Adult
(5)
Arthritis, Rheumatoid - Diagnostic Imaging
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy

Defining the Optimal Strategies for Achieving Drug-Free Remission in Rheumatoid Arthritis: A Narrative Review

Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses

Clinical trajectories of hand function impairment in systemic sclerosis: an unmet clinical need across disease subsets

After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?: Table 1

Discontinuation of biologics in patients with rheumatoid arthritis

Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study

P139 Rituximab in a large UK centre during the COVID-19 pandemic: the effects of employing a reduced dosing regimen on clinical response in Rheumatoid Arthritis patients

P12 Clinical responses, B cell depletion and treatment outcomes following rituximab biosimilar switch in RA: is there value in switching back?

Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments

Poly‐Refractory Rheumatoid Arthritis: An Uncommon Subset of Difficult to Treat Disease With Distinct Inflammatory and Noninflammatory Phenotypes

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study

Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis

Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?

COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1

After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?

191 Effectiveness and safety of switch to rituximab biosimilar with rheumatoid arthritis. a single centre experience

Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis

Effect of Fatigue, Older Age, Higher Body Mass Index, and Female Sex on Disability in Early Rheumatoid Arthritis in the Treatment‐to‐Target Era

After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?

The clinical, imaging and immunological phenotype of remission in inflammatory arthritis

Remission in inflammatory arthritis: a new immunological target

Infliximab for rheumatoid arthritis

Biomarkers: Strategies to predict outcome of rheumatoid arthritis

Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease‐modifying antirheumatic drugs: A clinical and imaging comparative study

Suchergebnisse filtern